{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:13:19Z","timestamp":1793851999669,"version":"4.6.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Individuals with kidney failure undergoing hemodialysis are at elevated risk for thromboembolic events. Factor (F) XI, which is in the intrinsic pathway of coagulation, is emerging as an attractive target for new anticoagulants that may be safer than existing agents. Osocimab\u2014an inhibitory FXIa antibody\u2014is a potential treatment option for such patients. We conducted a phase\u20092b, double-blind, placebo-controlled trial, in which 704 participants (448 male, 256 female) with kidney failure undergoing hemodialysis were randomized to receive lower- or higher-dose osocimab or placebo. In total, 686 participants (436 male, 250 female) received treatment for \u226418\u2009months (planned minimal treatment period of 6\u2009months). The co-primary outcomes were clinically relevant bleeding (a composite of major and clinically relevant nonmajor bleeding) and a composite of the incidence of moderate, severe or serious adverse events. Clinically relevant bleeding occurred in 16\/232 (6.9%) and 11\/224 (4.9%) participants who received lower- and higher-dose osocimab, respectively, and in 18\/230 participants (7.8%) who received a placebo. For the composite adverse event endpoint, incidences were 51%, 47% and 43% in the lower-dose osocimab, higher-dose osocimab and placebo groups, respectively. These results suggest that osocimab is associated with a low risk of bleeding and is generally well tolerated in this population; findings that require confirmation in larger trials. ClinicalTrials.gov identifier,\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04523220\">NCT04523220<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-023-02794-7","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T06:05:22Z","timestamp":1708063522000},"page":"435-442","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-7550","authenticated-orcid":false,"given":"Jeffrey I.","family":"Weitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3 B.","family":"Tank\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Floege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0140-2752","authenticated-orcid":false,"given":"Keith A. A.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-6245","authenticated-orcid":false,"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Thadhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2161-3151","authenticated-orcid":false,"given":"\u00c1kos F.","family":"Pap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Kubitza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang C.","family":"Winkelmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"CONVERT Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,16]]},"reference":[{"key":"2794_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"GBD Chronic Kidney Disease Collaboration.","year":"2020","unstructured":"GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 395, 709\u2013733 (2020).","journal-title":"Lancet"},{"key":"2794_CR2","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","volume":"389","author":"AC Webster","year":"2017","unstructured":"Webster, A. C., Nagler, E. V., Morton, R. L. & Masson, P. Chronic kidney disease. Lancet 389, 1238\u20131252 (2017).","journal-title":"Lancet"},{"key":"2794_CR3","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.kint.2021.08.028","volume":"100","author":"J Eikelboom","year":"2021","unstructured":"Eikelboom, J., Floege, J., Thadhani, R., Weitz, J. I. & Winkelmayer, W. C. Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target. Kidney Int. 100, 1199\u20131207 (2021).","journal-title":"Kidney Int."},{"key":"2794_CR4","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1681\/ASN.2007111207","volume":"20","author":"H Reinecke","year":"2009","unstructured":"Reinecke, H. et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J. Am. Soc. Nephrol. 20, 705\u2013711 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"2794_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s40697-014-0021-x","volume":"1","author":"MM Sood","year":"2014","unstructured":"Sood, M. M. et al. The three-year incidence of major hemorrhage among older adults initiating chronic dialysis. Can. J. Kidney Health Dis. 1, 21 (2014).","journal-title":"Can. J. Kidney Health Dis."},{"key":"2794_CR6","doi-asserted-by":"publisher","first-page":"h246","DOI":"10.1136\/bmj.h246","volume":"350","author":"M Jun","year":"2015","unstructured":"Jun, M. et al. The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. Br. Med. J. 350, h246 (2015).","journal-title":"Br. Med. J."},{"key":"2794_CR7","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","volume":"146","author":"SD Pokorney","year":"2022","unstructured":"Pokorney, S. D. et al. Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial. Circulation 146, 1735\u20131745 (2022).","journal-title":"Circulation"},{"key":"2794_CR8","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1161\/ATVBAHA.109.197178","volume":"30","author":"WA Schumacher","year":"2010","unstructured":"Schumacher, W. A., Luettgen, J. M., Quan, M. L. & Seiffert, D. A. Inhibition of factor XIa as a new approach to anticoagulation. Arterioscler Thromb. Vasc. Biol. 30, 388\u2013392 (2010).","journal-title":"Arterioscler Thromb. Vasc. Biol."},{"key":"2794_CR9","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","volume":"129","author":"M Preis","year":"2017","unstructured":"Preis, M. et al. Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events. Blood 129, 1210\u20131215 (2017).","journal-title":"Blood"},{"key":"2794_CR10","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1056\/NEJM200003093421004","volume":"342","author":"JC Meijers","year":"2000","unstructured":"Meijers, J. C., Tekelenburg, W. L., Bouma, B. N., Bertina, R. M. & Rosendaal, F. R. High levels of coagulation factor XI as a risk factor for venous thrombosis. N. Engl. J. Med. 342, 696\u2013701 (2000).","journal-title":"N. Engl. J. Med."},{"key":"2794_CR11","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1182\/blood-2009-05-219915","volume":"114","author":"M Cushman","year":"2009","unstructured":"Cushman, M., O\u2019Meara, E. S., Folsom, A. R. & Heckbert, S. R. Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology. Blood 114, 2878\u20132883 (2009).","journal-title":"Blood"},{"key":"2794_CR12","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1097\/FJC.0000000000000921","volume":"76","author":"CJ Beavers","year":"2020","unstructured":"Beavers, C. J. & Wayne, N. B. Osocimab: a novel agent in preventing venous thromboembolism. J. Cardiovasc. Pharmacol. 76, 645\u2013649 (2020).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"2794_CR13","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1016\/j.jmb.2019.09.008","volume":"431","author":"M Schaefer","year":"2019","unstructured":"Schaefer, M., Buchmueller, A., Dittmer, F., Stra\u00dfburger, J. & Wilmen, A. Allosteric inhibition as a new mode of action for BAY 1213790, a neutralizing antibody targeting the activated form of coagulation factor XI. J. Mol. Biol. 431, 4817\u20134833 (2019).","journal-title":"J. Mol. Biol."},{"key":"2794_CR14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1001\/jama.2019.20687","volume":"323","author":"JI Weitz","year":"2020","unstructured":"Weitz, J. I. et al. Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial. JAMA 323, 130\u2013139 (2020).","journal-title":"JAMA"},{"key":"2794_CR15","unstructured":"United States Renal Data System. 2022 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States (National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2022)."},{"key":"2794_CR16","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1111\/jth.12961","volume":"13","author":"IH Jaffer","year":"2015","unstructured":"Jaffer, I. H., Fredenburgh, J. C., Hirsh, J. & Weitz, J. I. Medical device-induced thrombosis: what causes it and how can we prevent it? J. Thromb. Haemost. 13, S72\u2013S81 (2015).","journal-title":"J. Thromb. Haemost."},{"key":"2794_CR17","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.2215\/CJN.11650919","volume":"15","author":"TA Mavrakanas","year":"2020","unstructured":"Mavrakanas, T. A., Garlo, K. & Charytan, D. M. Apixaban versus no anticoagulation in patients undergoing long-term dialysis with incident atrial fibrillation. Clin. J. Am. Soc. Nephrol. 15, 1146\u20131154 (2020).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"2794_CR18","doi-asserted-by":"crossref","unstructured":"Dahal, K., Kunwar, S., Rijal, J., Schulman, P. & Lee, J. Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies. Chest 149, 951\u2013959 (2016).","DOI":"10.1378\/chest.15-1719"},{"key":"2794_CR19","doi-asserted-by":"crossref","unstructured":"Reinecke, H. et al. A randomized controlled trial comparing apixaban to the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study. Circulation 147, 296\u2013309 (2023).","DOI":"10.1161\/CIRCULATIONAHA.122.062779"},{"key":"2794_CR20","unstructured":"Winkelmayer, W. C., for the RE-THINC investigators. Antithrombotic treatment with fesomersen vs. placebo in patients with ESKD on hemodialysis (ESKD-HD). In Proc. ASN Kidney Week TH\u2013PO976 (American Society of Nephrology, 2022)."},{"key":"2794_CR21","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/j.0006-341X.1999.01202.x","volume":"55","author":"IS Chan","year":"1999","unstructured":"Chan, I. S. & Zhang, Z. Test-based exact confidence intervals for the difference of two binomial proportions. Biometrics 55, 1202\u20131209 (1999).","journal-title":"Biometrics"},{"key":"2794_CR22","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/sim.4780091208","volume":"9","author":"CP Farrington","year":"1990","unstructured":"Farrington, C. P. & Manning, G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat. Med. 9, 1447\u20131454 (1990).","journal-title":"Stat. Med."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02794-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02794-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02794-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T08:21:05Z","timestamp":1708417265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02794-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2794"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02794-7","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"12 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.B.T., J.H., \u00c1.F.P. and D.K. are employees of Bayer; J.I.W. holds the Canada Research Chair (Tier\u2009I) in Thrombosis and the Heart and Stroke Foundation J.F. Mustard Chair in Cardiovascular Research at McMaster University, and has served as a consultant and received honoraria from Alnylam, Alexion, Anthos, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Merck, PhaseBio, Regeneron, Servier and VarmX; J.F. reports consultancy or speaker honoraria from Alnylam, AstraZeneca, Bayer, Boehringer Ingelheim, Calliditas, Chinook, Novartis, Omeros, Travere, VeraTx and Vifor; he also serves on data safety monitoring boards of trials by Novo Nordisk and Visterra. J.F. is an associate editor of <i>Kidney International<\/i>; K.A.A.F. reports grant funding from Bayer and AstraZeneca and consulting for Bayer, Medscape, Baim Institute for Clinical Research and the Thrombosis Research Institute; D.L.B. reports the following relationships: Advisory Boards of Angiowave, Bayer, Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, MyoKardia (now a subsidiary of Bristol Myers Squibb), NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences and Stasys; Board of Directors of Angiowave (stock options), Boston VA Research Institute, Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock), Society of Cardiovascular Patient Care and TobeSoft; Chair: Inaugural Chair, American Heart Association Quality Oversight Committee; Consultant: Broadview Ventures; Data Monitoring Committees: Acesion Pharma, Assistance Publique-H\u00f4pitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (Chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo; for the ABILITY-DM trial, funded by Concept Medical), Novartis, Population Health Research Institute; Rutgers University (for the National Institutes of Health (NIH)-funded MINT Trial); Honoraria: American College of Cardiology (Senior Associate Editor, <i>Clinical Trials and News<\/i>, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi\/Bristol Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, <i>Harvard Heart Letter<\/i>), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, <i>Journal of Invasive Cardiology<\/i>), <i>Journal of the American College of Cardiology<\/i> (Guest Editor; Associate Editor), K2P (co-chair, interdisciplinary curriculum), Level Ex, Medtelligence\/ReachMD (CME steering committees), MJH Life Sciences, Oakstone CME (Course Director, Comprehensive Review of Interventional Cardiology), Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and US national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, <i>Cardiology Today\u2019s Intervention<\/i>), Society of Cardiovascular Patient Care (Secretary\/Treasurer), WebMD (CME steering committees), Wiley (steering committee); Other: <i>Clinical Cardiology<\/i> (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Patent: Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women\u2019s Hospital who assigned to Lexicon; neither I nor Brigham and Women\u2019s Hospital receive any income from this patent); Research Funding: Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia (now a subsidiary of Bristol Myers Squibb), NirvaMed, Novartis, Novo Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, Youngene and 89Bio; Royalties: Elsevier (Editor, <i>Braunwald\u2019s Heart Disease<\/i>); Site Co-Investigator: Abbott, Biotronik, Boston Scientific, CSI, Endotronix, St. Jude Medical (now Abbott), Philips, SpectraWAVE, Svelte, Vascular Solutions; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Takeda; R.T. has received royalties from Thermo Fisher Scientific, and consulting fees from the US Food and Drug Administration and Fresenius Medical Care; he has served in a data safety committee for Alnylam, and scientific advisory committees for Aggamin, Bayer, Comanche Biopharma and Hero; and he is on the board of directors for CAMP4, and is an equity holder with Aggamin, CAMP4, Comanche Biopharma and Hero; W.C.W. holds the Gordon A. Cain Chair in Nephrology at Baylor College of Medicine, and has served as a consultant and has received honoraria from Akebia\/Otsuka, Ardelyx, AstraZeneca, Bayer, Boehringer Ingelheim\/Lilly, GlaxoSmithKline, Merck Sharp & Dohme\/Merck, Pharmacosmos, Reata, Unicycive and Zydus.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}